Audrey Sternberg - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Audrey Sternberg's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Audrey Sternberg
Verified
Associate Editorial Director, ONCOLOGY journal
Cranbury
Beats
Maryland, Politics, Maryland, Elections, Maryland, Education
Homosexuality, LGBT.
Content
By Audrey Sternberg Verified| Targeted Oncology Verified REGIMENS COMBINING IMMUNOTHERAPY (IO) plus tyrosine kinase inhibitors (TKIs) are now established, preferred choices in the treatment of previously untreated patients with advanced clear cell renal cell carcinoma (ccRCC), unseating earlier single-agent targeted therapies as the standard of care in this space. Multiple FDA-approved regimens mean patients and their care team have options when selecting the right therapy.
Addressing Disparities Through Enhancing Oncology Model and the Opportunity With Medically Integrated Dispensing
By Audrey Sternberg Verified| ONCOLOGY journal Verified The health equity conversation has come to the fore in a significant way since the emergence of the COVID-19 virus, with subsequent focus on the treatment of patients as individuals rather than hosts of a disease. As the oncology sector continually considers how disparities play into the overall success of patient care, attention to payer responsibility is essential.
By Audrey Sternberg Verified| Targeted Oncology Verified REGIMENS COMBINING IMMUNOTHERAPY (IO) plus tyrosine kinase inhibitors (TKIs) are now established, preferred choices in the treatment of previously untreated patients with advanced clear cell renal cell carcinoma (ccRCC), unseating earlier single-agent targeted therapies as the standard of care in this space. Multiple FDA-approved regimens mean patients and their care team have options when selecting the right therapy.
Company Info
ONCOLOGY journal
BioMed Central (BMC) is a prominent open-access publisher specializing in peer-reviewed biomedical research. Established in 2000, BMC was among the first commercial open-access publishers and has played a key role in promoting immediate access to original research articles. All articles published by BMC are freely available online, ensuring that scientific knowledge is accessible to a global audience. BMC publishes over 300 peer-reviewed journals across various disciplines, including biomedicine, physical sciences, mathematics, and engineering. Notable titles include *BMC Biology*, *BMC Medicine*, *Genome Biology*, and *Genome Medicine*. The company operates on an open-access model, utilizing article processing charges (APCs) to fund its publishing activities. BMC collaborates with leading institutions and societies to expand its journal offerings and enhance its presence in the scientific community.
Cranbury, United States
+44 20 3192 2009
Founded: 1998